Weill Neurohub-funded clinician-scientist Dr. Claire Clelland pictured with MAPT-FTD advocate Linde Jacobs at Clelland’s UCSF laboratory. Inset: Patient-derived cells created in the Clelland Lab.
Photos: Mike Kai Chen for the New York Times.
The Weill Neurohub Research Community has joined together to fight Tau-mediated neurodegeneration, including FTD.
Enabling research and building connections across world-class institutions
to address neurological and neuropsychiatric disease
The Weill Neurohub, established with the exceptional generosity of Joan and Sanford I. “Sandy” Weill and the Weill Family Foundation, brings together world-class researchers and clinicians at four premier West Coast research institutions to speed the development of new treatments for neurological and psychiatric diseases.
The Alliance for Therapies in Neuroscience (ATN) is a long-term research partnership with Genentech, a member of the Roche Group, and its parent company, Roche Holding AG.
Established in 2021, the goal of the ATN is to speed the development of new therapeutics for debilitating brain diseases and disorders of the central nervous system (CNS).
